32 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1206 - HNCG A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) Oral cavity and lips phase 2 Closed metastatic, RECIST 1.1
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- AG013-ODOM-201 A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy Head and Neck phase 2 Closed No prior gene therapy
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1
- CA209358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors Multiple phase 1/2 Closed ECOG 0 or 1
-
D-FR-01087-001
An international multi-center, open-label radioactivity escalation study to evaluate the safety, tolerability, biodistribution, and preliminary anti-tumor activity of 177Lu-3BP-227 for therapy in previously treated patients with advanced gastrointestinal cancers expressing neurotensin 1 receptors
Germ cell tumors
phase
1/2
Closed
*NTSR1 expression
*Measureable disease RECIST 1.1 - D5660C00004 A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Bones - soft tissue phase 1/2 Closed At least one measurable lesion
- EORTC 1420-HNCG-ROG Phase III study assessing the ?best of? radiotherapy compared to the ?best of? surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma Head and Neck phase 3 Open T1 or T2 N0,M0
- EORTC 1629 Late toxicity and long-term quality of life in head and neck cancer survivors Open
- EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis
- EVICTION A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer Multiple phase 1 Open Relasped/refractory patient
- I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Multiple phase 1 Closed RECIST 1.1, after standard trerapy
- IJB_2672 A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older Multiple phase 3 Closed vaccine, diarrhea, clostridium
- IJB_2728 Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention Solid tumors Open Metastatic, any tumors